Status:
UNKNOWN
Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
Lead Sponsor:
Miravant Pharmaceuticals
Conditions:
Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.
Exclusion
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT00157976
Start Date
September 1 2005
Last Update
December 1 2005
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Multiple Investigators
Sofia, Bulgaria
2
Multiple Investigators
Brno-Bohunice, Olomouc, Praha, Czechia
3
Multiple Investigators
Warsaw, Bydgoszcz, Lubin, Poland
4
Multiple Investigators
Bucharest, Romania